Mutations in EFHC1 Cause Juvenile Myoclonic Epilepsy
Suzuki T, Delgado-Escheat AV, Again K, Alonso ME, Shi J, Hara Y, Nishida M, Nowata T, Medina MT, Takeuchi T, Morita R, Bay D, Gnash S, Sugimoto Y, Niagara J, Bailey JN, Ochoa A, Jara-Prado A, Rasmussen A, Ramos-Peek J, Cordova S, Rubio-Donnadieu F, Inoue Y, Osawa M, Kaneko S, Oguni H, Mori Y, Yamakawa K
Nat Genet 2004;36:842–849
Juvenile myoclonic epilepsy (JME) is the most frequent cause of hereditary grand mal seizures. We previously mapped and narrowed a region associated with JME on chromosome 6p12–p11 (EJM1). Here, we describe a new gene in this region, EFHC1, which encodes a protein with an EF-hand motif. Mutation analyses identified five missense mutations in EFHC1 that cosegregated with epilepsy or EEG polyspike–wave in affected members of six unrelated families with JME and did not occur in 382 control individuals. Overexpression of EFHC1 in mouse hippocampal primary culture neurons induced apoptosis that was significantly lowered by the mutations. Apoptosis was specifically suppressed by SNX-482, an antagonist of R-type voltage-dependent Ca2+ channel (Cav2.3). EFHC1 and Cav2.3 immunomaterials overlapped in mouse brain, and EFHC1 coimmunoprecipitated with the Cav2.3 C terminus. In patch-clamp analysis, EFHC1 specifically increased R-type Ca2+ currents that were reversed by the mutations associated with JME.
COMMENTARY
Juvenile myoclonic epilepsy (JME) is a relatively common form of generalized epilepsy, which displays a complex inheritance pattern. Mutations in ion channel genes have been associated with JME and include the calcium channel subunit CACNB4 (1), the γ-aminobutyric acid (GABA) receptor subunit, GABRA1 (2), and the chloride channel CLCN2 (3). For each of these genes, mutations have been reported in only a single family with JME. Therefore mutations in ion channel genes are a rare cause of JME. Linkage studies combining numerous small families with JME have identified three additional loci: EJM1 on chromosome 6p12-p11, EJM2 on chromosome 15q14, and EJM3 on chromosome 6p21. To date, no causative gene has been identified from the EJM2 locus. The initially reported link between JME and the human lymphocyte antigen (HLA) region on chromosome 6p21 has now been designated EJM3, and association with BRD2 was recently described (4,5). Suzuki and colleagues have now uncovered the gene responsible for JME in families mapping to the EJM1 locus.
The EJM1 locus was refined to a 3.5-centimorgan region containing only 18 genes. Mutation analysis of these genes revealed five different mutations in the EFHC1 gene, in six Mexican families with JME. All mutations resulted in single amino acid substitutions. Two families had the same doubly heterozygous mutation and shared a common haplotype surrounding the EFHC1 gene, suggesting the two mutations arose on a founder chromosome common to both families. Mutations were found in six of 31 Mexican families and none of 12 European American families with JME. One large family from Belize carried a common polymorphism that segregated with JME. This polymorphism did not have any effect on normal EFHC1 function in the experiments described later, supporting the hypothesis that this family is linked to EFHC1 and that another, nearby mutation may be responsible for JME in this family. The fact that EFHC1 mutations were not found in all families mapping to the EJM1 locus implies that mutations may exist in noncoding regions that were not examined. Although splice sites and the upstream promoter region were sequenced, mutations may exist in control elements in other noncoding regions of the EFHC1 gene.
The EFHC1 protein is so named because it has an EF-hand domain, which functions as a calcium-binding motif. In mice, the EFHC1 protein is localized to the soma and dendrites of pyramidal neurons in the cortex and Purkinje cells in the cerebellum. In cultured mouse neurons transfected with wild-type EFHC1, cells had shorter neurites and fewer branches. After 2 days in culture, the cells began to shrink and die and were positive for markers of apoptosis. Cell death was reduced by the addition of any of the five EFHC1 mutants. Therefore the normal function of EFHC1 appears to induce apoptosis, and the JME mutations disrupt this complex process of programmed cell death.
Apoptosis involves genetic reprogramming of the cell to promote a cascade of biochemical and morphologic changes that result in cell death and elimination. Apoptosis can be triggered by many different stimuli, including calcium influx through plasma membrane channels. The presence of the calcium-sensing EF-hand motif prompted the authors to investigate whether EFHC1-induced apoptosis was associated with calcium channel activity. When calcium channels were blocked in neurons expressing EFHC1, cell-survival rate increased, implying that EFHC1 induces apoptosis through activation of calcium channels. Increased cell survival was seen only when R-type calcium channels (Cav2.3) were blocked. Blocking L-, T- or P/Q-type calcium channels had no effect on cell survival. With patch-clamp analyses in hamster kidney cells expressing Cav2.3, the authors demonstrated that EFHC1 greatly increased R-type calcium currents, providing further evidence that EFHC1 induces apoptosis specifically through activation of R-type calcium channels. EFHC1 is expressed in several brain regions that overlap with Cav2.3 expression. In the hippocampus, both Cav2.3 and EFHC1 are expressed in the soma and dendrites, implying that EFHC1 may bind directly to the calcium channel. With coimmunoprecipitation techniques, the authors confirmed that EFHC1 can directly interact with Cav2.3. They found that DM10 domains of EFHC1 bound to the C-terminus of Cav2.3 (and not the N- or P/Q-type channel subunits Cav 2.1 and Cav 2.2). In JME families, mutations are located within the DM10 domain region of EFHC1 shown to be involved in binding to Cav2.3, implying that the mutations disrupt binding. To summarize, the data suggest that mutations in EFHC1 interrupt normal apoptosis by preventing the EFHC1 protein from binding to and activating R-type calcium channels.
How can reducing cell death lead to seizures? During development, apoptosis is necessary for tissues and organs to acquire their unique structures and functions. Growth of tissue is determined by a quantitative relation between the rate of cell proliferation and the rate of cell death. The authors suggest that mutations in EFHC1 may cause unwanted neurons to be retained, resulting in increased density of neurons. Quantitative magnetic resonance imaging (MRI) has detected increases in cortical grey matter in JME patients, which may be due to an increase in the number of neurons (6). The increased density of neurons may cause JME by producing hyperexcitable circuits as a result of altered neuronal connectivity.
Polymorphisms in BRD2 have been associated with a clinically identical JME syndrome (4). BRD2 may also be involved in apoptosis, because of its proposed function as a mitogen-activated protein (MAP) kinase. MAP kinases are important mediators of signal transduction and play a key role in the regulation of many cellular processes, such as cell growth and proliferation, differentiation, and apoptosis. LGI1, the gene responsible for partial epilepsy with auditory features, also has been implicated in MAP kinase signaling (7). Valproate (VPA) is a commonly used and effective treatment for JME. It is interesting that VPA targets calcium channels (8) and also indirectly regulates a number of factors involved in cell-survival pathways (9), including MAP kinases. Mutations in cystatin B that cause PME of the Unverricht-Lundborg type also are associated with defects in apoptosis (10) However, this severe form of myoclonic epilepsy has been associated with increased neuronal cell death rather than increased cell survival.
An emerging role appears for several epilepsy genes, such as EFHC1, CSTB, BRD2, and LGI1, in the development and maintenance of normal neuronal structures, through cell-survival and cell-death pathways. Subtle increases in specific populations of neurons may be associated with JME, whereas extensive cell death is associated with more severe, progressive myoclonic epilepsy. Regardless of whether cell numbers are increased or decreased, it would disrupt the normal balance between excitatory and inhibitory circuits. Therefore a common epilepsy mechanism may involve abnormalities in functional connectivity that are due to subtle structural changes in the brain.
References
- 1.Escayg A, De Waard M, Lee DD, Bichet D, Wolf P, Mayer T, Johnston J, Baloh R, Sander T, Meisler MH. Coding and noncoding variation of the human calcium-channel beta(4)-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet. 2000;66:1531–1539. doi: 10.1086/302909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Cossette P, Liu L, Brisebois K, Dong H, Lortie A, Vanasse M, Saint-Hilaire J-M, Carmant L, Verner A, Lu WY, Wang YT, Rouleau GA. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet. 2002;31:184–189. doi: 10.1038/ng885. [DOI] [PubMed] [Google Scholar]
- 3.Haug K, Warnstedt M, Alekov AK, Sander T, Ramirez A, Poser B, Maljevic S, Hebeisen S, Kubisch C, Rebstock J, Horvath S, Hallmann K, Dullinger JS, Rau B, Haverkamp F, Beyenburg S, Schulz H, Janz D, Giese B, Muller-Newen G, Propping P, Elger CE, Fahlke C, Lerche H, Heils A. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet. 2003;33:527–532. doi: 10.1038/ng1121. [DOI] [PubMed] [Google Scholar]
- 4.Pal DK, Evgrafov OV, Tabares P, Zhang F, Durner M, Greenberg DA. BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy. Am J Hum Genet. 2003;73:261–270. doi: 10.1086/377006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wallace R. Susceptibility gene for juvenile myoclonic epilepsy rings true. Epilepsy Currents. 2004;4:9–10. doi: 10.1111/j.1535-7597.2004.04103.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Woermann FG, Free SL, Koepp MJ, Sisodiya SM, Duncan JS. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI. Brain. 1999;122:2101–2108. doi: 10.1093/brain/122.11.2101. [DOI] [PubMed] [Google Scholar]
- 7.Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK. LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem. 2004;279:23151–2317. doi: 10.1074/jbc.M314192200. [DOI] [PubMed] [Google Scholar]
- 8.Ulrich ML, Rotzinger S, Asghar SJ, Jurasz P, Tanay VA, Dunn SM, Radomski M, Greenshaw A, Silverstone PH. Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels. J Psychiatry Neurosci. 2003;28:115–125. [PMC free article] [PubMed] [Google Scholar]
- 9.Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry. 2002;7(suppl 1):S46–S56. doi: 10.1038/sj.mp.4001018. [DOI] [PubMed] [Google Scholar]
- 10.Shannon P, Pennacchio LA, Houseweart MK, Minassian BA, Myers RM. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J Neuropathol Exp Neurol. 2002;61:1085–1091. doi: 10.1093/jnen/61.12.1085. [DOI] [PubMed] [Google Scholar]